Literature DB >> 29887370

Reappraising the cardiosafety of dihydroartemisinin-piperaquine.

Pere Millat-Martínez1, Quique Bassat2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29887370     DOI： 10.1016/S1473-3099(18)30360-8

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  3 in total

1.  Evaluation of the effects on the QT-interval of 4 artemisinin-based combination therapies with a correction-free and heart rate-free method.

Authors:  Christian Funck-Brentano; Nouhoum Ouologuem; Stephan Duparc; Mathieu Felices; Sodiomon B Sirima; Issaka Sagara; Issiaka Soulama; Jean-Bosco Ouedraogo; Abdoul H Beavogui; Isabelle Borghini-Fuhrer; Yasmin Khan; Abdoulaye A Djimdé; Pascal Voiriot
Journal:  Sci Rep       Date:  2019-01-29       Impact factor: 4.379

2.  Effects of Dihydroartemisinin-Piperaquine Phosphate and Artemether-Lumefantrine on QTc Interval Prolongation.

Authors:  Christian Funck-Brentano; Antonella Bacchieri; Giovanni Valentini; Silvia Pace; Silva Tommasini; Pascal Voiriot; David Ubben; Stephan Duparc; Eric Evene; Mathieu Felices; Marco Corsi
Journal:  Sci Rep       Date:  2019-01-28       Impact factor: 4.379

3.  Impact and operational feasibility of adding malaria infection screening using an ultrasensitive RDT for placental and fetal outcomes in an area of high IPTP-SP coverage in Burkina Faso: the ASSER MALARIA pilot study protocol.

Authors:  Marc Christian Tahita; Paul Sondo; Berenger Kabore; Hamidou Ilboudo; Toussaint Rouamba; Hyacinthe Sanou; Kadija Ouédraogo; Adélaïde Compaoré; Palpouguini Lompo; Florence Ouedraogo; Seydou Sawadogo; Karim Derra; Yabré Edmond Sawadogo; Athanase M Somé; Macaire Nana; Hermann Sorgho; Maminata Traore-Coulibaly; Quique Bassat; Halidou Tinto
Journal:  Pilot Feasibility Stud       Date:  2022-10-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.